Literature DB >> 2821123

Polymyxin B moderates acidosis and hypotension in established, experimental gram-negative septicemia.

P M Flynn1, J L Shenep, D C Stokes, D Fairclough, W K Hildner.   

Abstract

Polymyxin B (PMB), an antibiotic, and sodium deoxycholate (NaD), a bile salt, are surface-active agents. Each protected mice against an otherwise lethal challenge with purified endotoxin (P less than .001). To determine if either of these agents was effective in treating established, overwhelming gram-negative septicemia, we infected rabbits by intraperitoneal injection of Escherichia coli K1. Animals were treated with moxalactam 1 hr after infection, then randomly assigned to groups receiving either saline, PMB, or NaD. Serial samples of blood were assayed for bacterial concentration, levels of plasma endotoxin, arterial blood gases, and complete blood cell counts. Physiologic functions were monitored continuously. Although levels of bacteremia and endotoxemia were similar in all three groups, rabbits receiving PMB had significantly higher mean arterial blood pressure, blood pH, and bicarbonate concentrations than did control rabbits (P less than .05). Rabbits receiving NaD fared no better than controls. In this model, PMB moderates some of the deleterious effects of established, overwhelming gram-negative bacterial sepsis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821123     DOI: 10.1093/infdis/156.5.706

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

Review 1.  Sepsis management and antiendotoxin therapy after nebacumab. A reappraisal.

Authors:  J C Hurley
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

Review 2.  Clinical relevance of antibiotic-induced endotoxin release.

Authors:  J M Prins; S J van Deventer; E J Kuijper; P Speelman
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

3.  Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent.

Authors:  J J Drabick; A K Bhattacharjee; D L Hoover; G E Siber; V E Morales; L D Young; S L Brown; A S Cross
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

4.  Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide.

Authors:  R L Danner; K A Joiner; M Rubin; W H Patterson; N Johnson; K M Ayers; J E Parrillo
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 5.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

6.  Effects of two magainin peptides on eicosanoid release from rat peritoneal macrophages.

Authors:  G Matera; J A Cook; J Geisel; S H Ashton; W C Wise; A Focá; B A Berkowitz; P V Halushka
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis.

Authors:  Y Lin; W J Leach; W S Ammons
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

8.  Dependence of endotoxin-induced vascular hyporeactivity on extracellular L-arginine.

Authors:  C A Schott; G A Gray; J C Stoclet
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

Review 9.  Endotoxemia: methods of detection and clinical correlates.

Authors:  J C Hurley
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 10.  Towards clinical applications of anti-endotoxin antibodies; a re-appraisal of the disconnect.

Authors:  James C Hurley
Journal:  Toxins (Basel)       Date:  2013-12-18       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.